Cytokinetics Announces Presentation of Additional Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at Heart Failure 2016 Congress

Treatment with Omecamtiv Mecarbil Produced Progressive and Sustained Effects  On Cardiac Function as Measured by Reductions in Diastolic Ventricular Volume and NT-proBNP

SOUTH SAN FRANCISCO, Calif., May 23, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK ) today announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2b trial evaluating omecamtiv mecarbil in patients with chronic heart failure, were presented in a poster titled “COSMIC-HF: Improved Contractility and Evolution of Ventricular Remodeling through Time” at Heart Failure 2016, the annual congress of the Heart Failure Association of the European Society of Cardiology, in Florence, Italy.  The results presented showed that omecamtiv mecarbil improved left ventricular (LV) systolic function, LV end-diastolic volume and NT-proBNP over time, suggesting potentially favorable ventricular remodeling and progressive reduction in myocardial wall stress. Omecamtiv mecarbil , a novel investigational cardiac myosin activator that increases cardiac contractility, is being developed by Amgen in collaboration with Cytokinetics for the potential treatment of heart failure.

“For the first time, we have evidence that increasing cardiac contractility by chronic treatment with omecamtiv mecarbil may result in a progressive reduction in ventricular size,” said Fady I. Malik, MD, PhD, Cytokinetics' Executive Vice President, Research and Development. “We are preparing for a potential Phase 3 program in collaboration with Amgen in which we would learn if these effects on cardiac function are durable over longer periods of treatment and may also translate to improved cardiovascular outcomes.”  

COSMIC-HF: Expansion Phase Design and Results  

The expansion phase of COSMIC-HF evaluated the pharmacokinetics, pharmacodynamics, safety and tolerability of oral omecamtiv mecarbil in 448 patients with chronic heart failure and left ventricular systolic dysfunction. Patients were randomized 1:1:1 to placebo, to omecamtiv mecarbil 25 mg twice daily, or to a dose titration group in which an initial dose of 25 mg twice daily could be increased to 50 mg twice daily depending on the plasma concentration of omecamtiv mecarbil after two weeks of treatment with the 25 mg twice daily dose. Data from the expansion phase were presented as a Late-Breaking Clinical Trial at the American Heart Association’s Scientific Sessions in November, 2015 and showed that this dose titration strategy maintained concentrations of omecamtiv mecarbil within a range associated with potentially beneficial pharmacodynamic effects avoiding excessive concentrations.

Placebo-corrected data from the dose titration group are shown in the table below.  Increases in systolic ejection time (SET) and stroke volume, and decreases in LV end-systolic volume, were similar after both 12 and 20 weeks of treatment with omecamtiv mecarbil ; however, LV end-diastolic volume decreased progressively from 12 to 20 weeks, with the decrease after 20 weeks nearly twice that observed after 12 weeks.  NT-proBNP (a biomarker that is elevated in heart failure, with higher elevations reflecting more severe heart failure) also fell progressively over time and, of particular note, had declined even further four weeks after treatment discontinuation (‑1306 ± 376 pg/mL; p=0.0006).  Heart rate also declined significantly after 2, 12 and 20 weeks of treatment ranging from 2-4 beats per minute and returning nearly to baseline four weeks after treatment discontinuation (-1.2±1.2 beats/min: p = 0.29).

Endpoint Baseline* Changes from Baseline* (p value for change on omecamtiv mecarbil vs. placebo)
2 Weeks 12 weeks 20 weeks
 Systolic Ejection Time (msec) 298 ± 333 Not measured 22 ± 3 (p < 0.0001) 25 ± 3 (p < 0.0001)
 Stroke Volume (mL) 52.4 ± 14.9 3.2 ± 1.6 (p = 0.038) 3.6 ± 1.6 (p = 0.022)
 LV end-systolic volume (mL) 157.1 ± 77.7 ‑9.9 ± 3.8 (p = 0.009) -11.2 ± 3.9 (p = 0.005)
 LV end-diastolic volume (mL) 215.9 ± 88.8 -5.8 ± 4.2 (p = 0.17) -10.7 ± 4.6 (p = 0.021)
 NT-proBNP (pg/mL)  (Baseline is median [Q1, Q3]) 1719 [881, 3060] ‑302 ± 204 (p = 0.14) -623 ± 364 (p = 0.087) -970 ± 357 (p = 0.007)
 Heart rate (beats/min) 70 ± 12 ‑2.2 ± 0.8 (p = 0.007) -4.0 ± 1.0 (p < 0.0001) -3.0 ± 1.1 (p = 0.007)
 *mean ± SD unless otherwise noted

About Omecamtiv Mecarbil

Omecamtiv mecarbil is a novel cardiac myosin activator. Cardiac myosin is the cytoskeletal motor protein in the cardiac muscle cell that is directly responsible for converting chemical energy into the mechanical force resulting in cardiac contraction. Cardiac myosin activators are thought to accelerate the rate-limiting step of the myosin enzymatic cycle and shift the enzymatic cycle in favor of the force-producing state. Preclinical research has shown that cardiac myosin activators increase contractility in the absence of changes in intracellular calcium in cardiac myocytes. Omecamtiv mecarbil is being developed by Amgen in collaboration with Cytokinetics. Amgen holds an exclusive, worldwide license to omecamtiv mecarbil and related compounds, subject to Cytokinetics’ specified development and commercialization rights. Les Laboratoires Servier obtained an exclusive option to commercialize omecamtiv mecarbil in Europe.

About Cytokinetics

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv , a fast skeletal muscle troponin activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of ALS. Cytokinetics retains the right to develop and commercialize tirasemtiv . Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil , a novel cardiac muscle activator, for the potential treatment of heart failure. Cytokinetics is collaborating with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy and chronic obstructive pulmonary disease. Amgen holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and Astellas holds an exclusive license worldwide to develop and commercialize CK-2127107. Both licenses are subject to Cytokinetics' specified development and commercialization participation rights. For additional information about Cytokinetics, visit http://www.cytokinetics.com/

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, the properties and potential benefits of Cytokinetics’ drug candidates, including omecamtiv mecarbil ; plans and timing of the ongoing Phase 2 clinical trial of omecamtiv mecarbil and a potential Phase 3 clinical trial of omecamtiv mecarbil ; and the potential for eventual regulatory approval, commercialization and launch of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to Amgen's decisions with respect to the design, initiation, conduct, timing and continuation of development activities for omecamtiv mecarbil; potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics' drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results, patient enrollment for or conduct of clinical trials may be difficult or delayed, Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutic efficacy, the U.S. Food and Drug Administration or foreign regulatory agencies may delay or limit Cytokinetics' or its partners' ability to conduct clinical trials, and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; and Cytokinetics may incur unanticipated research and development and other costs or be unable to obtain additional financing necessary to conduct development of its products; standards of care may change, rendering Cytokinetics' drug candidates obsolete; competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics' drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release.

 

Contact: Cytokinetics Diane Weiser Vice President, Corporate Communications, Investor Relations (415) 290-7757

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Geothermal AI Nodes Take Aim at Stranded Well Power

Updated Category News Views 175

Millions of idle wells are sitting under America like unwanted basement clutter, and GEIOS GEOFLEX thinks some can become small, self-contained AI power plants. That is the provocative idea behind its Dark Token Factory partnership with Aiden Digital Labs: bolt an autonomous compute module onto an abandoned or non-producing oil and gas well, pull geothermal heat from...

Continue Reading
Clickstop's Urbana Expansion Bets on Durable Demand

Updated Category News Views 63

A patch of turned Iowa dirt can say plenty about a company’s nerve. Clickstop broke ground in Urbana on Nov. 19, 2026, for a 43,000-square-foot building, and the message is pretty plain: management believes its recent growth has legs. For a privately held, employee-owned operator serving trucking, construction, lifting and rigging, that is not a casual decision....

Continue Reading
Cineverse Sets Wolf Creek Return for March 19, 2027

Updated Category News Views 121

A sunburned serial killer is heading back to theaters, and Cineverse has finally put a date on it: March 19, 2027. WOLF CRE3K, formerly called Wolf Creek: Legacy, brings John Jarratt back as Mick Taylor for the third film in the Australian horror franchise. For NASDAQ:CNVS investors, this is not the kind of announcement that lets anyone pencil in revenue with a straight...

Continue Reading
DHC’s Ulta Rollout Gets a Useful Pricing Correction

Updated Category News Views 49

A face-wash price tag just became the most revealing part of DHC’s Ulta expansion. The company corrected an earlier announcement that had listed its new Deep Cleansing Face Wash at $31.50; the actual price is $19.00. That may sound like tiny housekeeping, and in the grand scheme it is, but consumer brands live or die on this kind of detail. A cleanser priced near $20...

Continue Reading
Hard Rock Tampa Bets $30 Million on Smoke-Free Play

Updated Category News Views 71

Cigarette smoke is getting treated like a revenue problem in Tampa, and that is a far more interesting signal than another ribbon-cutting photo. Seminole Hard Rock Hotel & Casino Tampa opened The Breeze: A Smoke-Free Experience by Hard Rock on Nov. 19, 2026, following a $30 million transformation aimed at guests who want clean-air casino time from arrival through...

Continue Reading
IT Tech Packaging's Going-Concern Warning Lands Hard

Updated Category News Views 91

A paper maker can survive plenty of ugly quarters; it cannot casually shrug off an auditor questioning whether it can keep operating. That is the cold part of IT Tech Packaging's Nov. 19 disclosure. Its newly filed Form 10-K for the year ended Dec. 31, 2025 carries a “Material Uncertainty Related to Going Concern” paragraph from Audit Alliance LLP. Nobody should dress...

Continue Reading
Barcelona Housing Summit Puts Affordability on the Map

Updated Category News Views 186

A packed Barcelona hall cannot magically unjam a housing market, but it can force the grown-ups in the room to stare at the mess. Housing World Summit, known as HOWS Barcelona, closed its first edition with 1,530 attendees and a broad cast: city officials, governments, developers, investors, third-sector groups and academics. That mix matters because affordable housing is...

Continue Reading
Decibel's Export Engine Masks a Domestic Sales Slip

Updated Category News Views 87

Decibel’s overseas business is doing the heavy lifting, and it is not doing it quietly. Third-quarter net revenue reached $35.1 million, up 7% from a year earlier, while international sales jumped 44% to a record $12.1 million. That split matters more than the headline. Canadian adult-use sales fell 6% to $23.0 million, which means the company is proving it can find...

Continue Reading
SciBase Sets Its 2027 AGM Nominating Committee Early

Updated Category News Views 94

Four names on a committee roster rarely make anyone pound the table, and they should not. Still, SciBase Holding has put an important bit of corporate housekeeping in place for its 2027 Annual General Meeting: the nominating committee that will handle shareholder-facing governance work ahead of the May 20 meeting in Stockholm. For a small listed medical-technology...

Continue Reading
JDEnergy's RE+ Push Meets a Grid Hungry for Storage

Updated Category News Views 64

Certification Is Useful, Not a Victory Lap A battery box earning a safety certificate is not usually thrilling stuff, but the timing matters here. On Nov. 19, 2026, JDEnergy laid out its North American storage pitch at RE+ in Las Vegas while electricity demand is getting shoved higher by industrial buildout and AI data centers. Add more variable renewable generation to an...

Continue Reading

Top 5 Most Recently Viewed Articles

McDonald's Earnings Anticipation: Insights from Analysts Ahead

Updated Category News Views 110

Anticipating McDonald's Q3 Earnings Report As the third quarter approaches, McDonald's Corporation (NYSE: MCD) is preparing to unveil its earnings report, sparking interest among investors and analysts alike. This significant event is anticipated to occur just before the opening bell, offering crucial insights into the company's financial health and market position. What...

Continue Reading
BC Platforms Unveils Game-Changing AI Technology for Researchers

Updated Category News Views 281

BC Platforms Introduces BC Catalyst for Precision Medicine BC Platforms has officially launched BC Catalyst, an innovative AI-native analytics product designed to enhance precision medicine. This breakthrough technology integrates genomic and real-world data, allowing for actionable insights throughout the entire drug lifecycle. With BC Catalyst, the company aims to...

Continue Reading
TestFly Expands QA Testing Services with Red Cerberus Deal

Updated Category News Views 300

TestFly Enhances Service Offerings Through Acquisition TestFly, a prominent provider of innovative quality assurance testing solutions for the video game and mobile gaming sectors, has undertaken a significant move by acquiring Red Cerberus. This acquisition is set to transform the landscape of video game quality assurance by integrating Red Cerberus' expertise and...

Continue Reading
Unveiling Insurance Industry Abuses: New Podcast Series Launch

Updated Category News Views 173

Consumer Watchdog Introduces Insightful Podcast Series Smoke & Mirrors Debuts Today, Investigating Insurance Underpayments and Consumer Resilience Today marks the launch of a groundbreaking podcast series from Consumer Watchdog, titled "Smoke & Mirrors: Investigating Home Insurance Abuses," aimed at shedding light on the troubling practices that major insurance firms...

Continue Reading
MongoDB’s Leadership Change: Opportunities for Investors Ahead

Updated Category News Views 171

Understanding the Leadership Shift at MongoDB Recently, MongoDB (NASDAQ: MDB) has been a significant topic of discussion in investing circles due to its remarkable stock performance. After the stock's impressive rise from $188.81 to about $358 per share, many are questioning the right strategy—should investors lock in their profits now or remain committed for the long...

Continue Reading